Nov 20, 2006 by Brian LawlerOne-and-a-Half Setbacks for ExelixisDrug development is a long process usually involving many setbacks and failures, even for the most successful drug makers.
Nov 17, 2006 by Brian LawlerJohnson & Johnson's Good DealThe company might wind up with an even better drug-eluting stent than it already has.
Nov 17, 2006 by Brian LawlerGenentech Gets Another ApprovalToday, Genentech finally received formal approval to market its breast cancer therapy Herceptin for the early stages.
Nov 13, 2006 by Brian LawlerBiovail Is Getting CheapOne of the drugmaker's products could face generic competition in the next year.
Nov 13, 2006 by Brian LawlerKos' Swan SongThe company releases what will probably be its last earnings announcement before a buyout.
Nov 13, 2006 by Brian LawlerKing Not Loving Its ShareholdersManagement has made it clear where its priorities are.
Nov 10, 2006 by Brian LawlerWatson Doesn't Wow InvestorsWatson made a $2 billion buyout of smaller competitor Andrx and finally closed the deal this quarter.
Nov 10, 2006 by Brian LawlerDendreon Pending ApprovalA lot is riding on what the FDA will say about the company's drug for prostate cancer.
Nov 10, 2006 by Brian LawlerPolyMedica Produces. Sort OfWhen sales are growing faster than earnings, it's never a good sign.
Nov 9, 2006 by Brian LawlerThe Best Blue Chip for 2007: GlaxoSmithKlineHere's a blue-chip prescription for your portfolio.
Nov 9, 2006 by Brian LawlerNoven Might Be in a Purple PatchA new treatment for attention deficit disorder is selling so briskly, it could mean big money.
Nov 9, 2006 by Brian LawlerHospira's Flatlining SalesThere's no good news to be found in this supplier's medicine chest.
Nov 8, 2006 by Brian LawlerStumbling Block for AdolorAnother approvable letter from the FDA means investors may have to be patient.
Nov 8, 2006 by Brian LawlerTeva Is Rolling in Cash AgainIt's a good time to be a generic drug company.
Nov 8, 2006 by Brian LawlerWill Santarus Heal Investors' Heartburn?This pharma's fortunes will rise or fall on its single drug.
Nov 8, 2006 by Brian LawlerBarr's Wounded QuarterThe loss of an exclusivity deal slashes Barr's generic revenues.
Nov 7, 2006 by Brian LawlerAbraxis AdvancesIts platform technology could improve existing drugs, much to investors' excitement.
Nov 6, 2006 by Brian LawlerMixed Feelings About PDLThird-quarter results look fine on the surface, but does deeper digging reveal some reasons to be concerned?
Nov 6, 2006 by Brian LawlerThe Impending Verdict on MomentaThe drug developer isn't willing to wait for potential legislation on generic drugs.
